Last updated: 2026-09-06 03:42:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Ocular Therapeutix, Inc. (OCUL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $10.65, with a market capitalization of $2.39B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.23 to $16.44. This page covers its latest market performance, valuation, price trends and company information.
$2.39B | |
$10.64 | |
$44.19 | |
$2.00 | |
$10.64 | |
961.62K | |
-- | |
-- | |
$16.44 | |
$6.23 | |
-- | |
-- |
Ocular Therapeutix, Inc. (OCUL) last closed at $10.64 as of 2026-09-04 23:59:00, unchanged from the previous close of $10.64.
During the latest regular trading session, OCUL traded between $2.00 and $44.19, with a volume of 961.62K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Ocular Therapeutix, Inc. (OCUL) moved from $10.30 to $10.65, representing a gain of 3.35% ($0.34).
The stock traded between $10.52 and $10.77 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 1.66 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 43.2%
OCUL is currently trading at $10.65, placing it 43.2% of the way from its 52-week low of $6.23 to its 52-week high of $16.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 325 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Ocular Therapeutix, Inc. (OCUL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.